Marksans Pharma Limited (BOM:524404)
India · Delayed Price · Currency is INR 321.25
+0.65 (0.20%)
At close: Aug 21, 2026
Marksans Pharma Market Cap
Marksans Pharma has a market cap or net worth of 145.6 billion as of August 21, 2026. Its market cap has increased by 77.03% in one year.
Market Cap
145.60B
Enterprise Value
139.42B
Revenue
31.72B
Ranking
n/a
PE Ratio
28.18
Stock Price
321.25
ChartMarket Cap Chart
Since December 13, 2006, Marksans Pharma's market cap has increased from 3.65B to 145.60B, an increase of 3,887.38%. That is a compound annual growth rate of 20.57%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 21, 2026 | 145.60B | 78.21% |
| Dec 31, 2025 | 81.70B | -39.22% |
| Dec 31, 2024 | 134.43B | 84.14% |
| Dec 29, 2023 | 73.00B | 210.96% |
| Dec 30, 2022 | 23.48B | -4.66% |
| Dec 31, 2021 | 24.63B | -0.80% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Rubicon Research | 285.49B |
| Granules India | 208.57B |
| Caplin Point Laboratories | 192.34B |
| AstraZeneca Pharma India | 187.61B |
| Jubilant Pharmova | 139.25B |
| CORONA Remedies | 131.04B |
| Viyash Scientific | 120.57B |
| Procter & Gamble Health | 97.28B |